{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:13:01Z","timestamp":1792653181334,"version":"4.5.0"},"reference-count":113,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Transthyretin (TTR) is a thyroid hormone-binding protein which transports thyroxine from the bloodstream to the brain. The structural stability of TTR in tetrameric form is crucial for maintaining its original functions in blood or cerebrospinal fluid (CSF). The altered structure of TTR due to genetic mutations or its deposits due to aggregation could cause several deadly diseases such as cardiomyopathy and neuropathy in autonomic, motor, and sensory systems. The early diagnoses for hereditary amyloid TTR with cardiomyopathy (ATTR-CM) and wild-type amyloid TTR (ATTRwt) amyloidosis, which result from amyloid TTR (ATTR) deposition, are difficult to distinguish due to the close similarities of symptoms. Thus, many researchers investigated the role of ATTR as a biomarker, especially its potential for differential diagnosis due to its varying pathogenic involvement in hereditary ATTR-CM and ATTRwt amyloidosis. As a result, the detection of ATTR became valuable in the diagnosis and determination of the best course of treatment for ATTR amyloidoses. Assessing the extent of ATTR deposition and genetic analysis could help in determining disease progression, and thus survival rate could be improved following the determination of the appropriate course of treatment for the patient. Here, the perspectives of ATTR in various diseases were presented.<\/jats:p>","DOI":"10.3390\/ijms20122982","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T10:43:32Z","timestamp":1560941012000},"page":"2982","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7529-0423","authenticated-orcid":false,"given":"Gil Yong","family":"Park","sequence":"first","affiliation":[{"name":"Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, Seongnam-si 13120, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-8386","authenticated-orcid":false,"given":"Angelo","family":"Jamerlan","sequence":"additional","affiliation":[{"name":"Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, Seongnam-si 13120, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Hwan","family":"Shim","sequence":"additional","affiliation":[{"name":"Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, Seongnam-si 13120, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Soo A.","family":"An","sequence":"additional","affiliation":[{"name":"Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, Seongnam-si 13120, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI101335","article-title":"An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins","volume":"21","author":"Kabat","year":"1942","journal-title":"J. Clin. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0006-291X(85)91956-4","article-title":"Localization of the human prealbumin gene to chromosome 18","volume":"129","author":"Wallace","year":"1985","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum. Mutat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25832","DOI":"10.1074\/jbc.M109.017657","article-title":"Amyloidogenic Potential of Transthyretin Variants: Insights from structural and computational analyses","volume":"284","author":"Cendron","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00439-014-1499-0","article-title":"Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt)","volume":"134","author":"Sikora","year":"2015","journal-title":"Hum. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41431-019-0337-1","article-title":"Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data","volume":"27","year":"2019","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.bbadis.2013.09.011","article-title":"Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro","volume":"1832","author":"Cascella","year":"2013","journal-title":"Biochim. Et Biophys. Acta (Bba)\u2014Mol. Basis Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/bi4001613","article-title":"Transthyretin as both a sensor and a scavenger of \u03b2-amyloid oligomers","volume":"52","author":"Yang","year":"2013","journal-title":"Biochemistry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1021\/acs.jmedchem.7b00428","article-title":"Insights on the Interaction between Transthyretin and A\u03b2 in Solution. A Saturation Transfer Difference (STD) NMR Analysis of the Role of Iododiflunisal","volume":"60","author":"Gimeno","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"19423","DOI":"10.1523\/JNEUROSCI.2561-13.2013","article-title":"Mechanisms of Transthyretin Inhibition of \u03b2-Amyloid Aggregation in vitro","volume":"33","author":"Li","year":"2013","journal-title":"J. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1007\/s12035-016-0065-2","article-title":"Rare Genetic Variants of the Transthyretin Gene Are Associated with Alzheimer\u2019s Disease in Han Chinese","volume":"54","author":"Xiang","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/(SICI)1098-2825(1999)13:6<273::AID-JCLA4>3.0.CO;2-X","article-title":"Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: A practical, simple and clinically relevant approach in a large cohort","volume":"13","author":"Ritchie","year":"1999","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1523\/JNEUROSCI.23-05-01949.2003","article-title":"Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption","volume":"23","author":"Marchi","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bpc.2014.02.002","article-title":"Mutation and low pH effect on the stability as well as unfolding kinetics of transthyretin dimer","volume":"189","author":"Xue","year":"2014","journal-title":"Biophys. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jsb.2011.12.022","article-title":"Hydrogen-bond network and pH sensitivity in transthyretin: Neutron crystal structure of human transthyretin","volume":"177","author":"Yokoyama","year":"2012","journal-title":"J. Struct. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0022-2836(78)90368-6","article-title":"Structure of prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 \u00c5","volume":"121","author":"Blake","year":"1978","journal-title":"J. Mol. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1111\/j.1742-4658.2009.07243.x","article-title":"Evolutionary changes to transthyretin: Structure\u2013function relationships","volume":"276","author":"Prapunpoj","year":"2009","journal-title":"Febs J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"12956","DOI":"10.1073\/pnas.95.22.12956","article-title":"Inhibiting transthyretin conformational changes that lead to amyloid fibril formation","volume":"95","author":"Peterson","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/iub.340","article-title":"Aboard transthyretin: From transport to cleavage","volume":"62","author":"Liz","year":"2010","journal-title":"IUBMB Life"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1021\/bi00673a014","article-title":"Negative cooperativity in the binding of thyroxine to human serum prealbumin","volume":"14","author":"Ferguson","year":"1975","journal-title":"Biochemistry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1107\/S0907444996003046","article-title":"Structures of human transthyretin complexed with thyroxine at 2.0 \u00c5 resolution and 3\u2032,5\u2032-dinitro-N-acetyl-L-thyronine at 2.2 \u00c5 resolution","volume":"52","author":"Wojtczak","year":"1996","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/bbrc.1995.1633","article-title":"Epitope mapping of a monoclonal antibody that blocks the binding of retinol-binding protein to its receptor","volume":"210","author":"Melhus","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_23","unstructured":"Newcomer, M.E., and Ong, D.E. (2000). Retinol Binding Protein and Its Interaction with Transthyretin, Landes Bioscience."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.7754382","article-title":"Structure of a complex of two plasma proteins: Transthyretin and retinol-binding protein","volume":"268","author":"Monaco","year":"1995","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM198404193101605","article-title":"Vitamin A and retinoids in health and disease","volume":"310","author":"Epstein","year":"1984","journal-title":"New Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1152\/physrev.1984.64.3.873","article-title":"Multiple functions of vitamin A","volume":"64","author":"Wolf","year":"1984","journal-title":"Physiol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1021\/bi00160a023","article-title":"Interactions of retinol with binding proteins: Studies with retinol-binding protein and with transthyretin","volume":"31","author":"Noy","year":"1992","journal-title":"Biochemistry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"27207","DOI":"10.1074\/jbc.M101024200","article-title":"Tetramer Dissociation and Monomer Partial Unfolding Precedes Protofibril Formation in Amyloidogenic Transthyretin Variants","volume":"276","author":"Quintas","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cardfail.2009.04.003","article-title":"Familial Amyloid Cardiomyopathy Due to TTR Mutations: An underground Cause of Restrictive Cardiomyopathy","volume":"15","author":"Ruberg","year":"2009","journal-title":"J. Card. Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/0006-291X(88)90188-X","article-title":"Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin","volume":"154","author":"Cornwell","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: Recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","article-title":"Senile systemic amyloidosis presenting with heart failure","volume":"165","author":"Connors","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: Updates in diagnosis and management","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_35","first-page":"178","article-title":"Amyloid heart disease: New frontiers and insights in pathophysiology, diagnosis, and management","volume":"32","author":"Hassan","year":"2005","journal-title":"Tex. Heart Inst. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0002-9149(97)89403-9","article-title":"Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis","volume":"77","author":"Dubrey","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.med.47.1.241","article-title":"Explaining fatigue in congestive heart failure","volume":"47","author":"Drexler","year":"1996","journal-title":"Annu. Rev. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: The Framingham study","volume":"285","author":"McKee","year":"1971","journal-title":"New Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","article-title":"Senile systemic amyloidosis presenting with heart failure: A comparison with light chain\u2013associated amyloidosis","volume":"165","author":"Ng","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/jmbi.2000.4220","article-title":"Search for intermediate structures in transthyretin fibrillogenesis: Soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils","volume":"304","author":"Redondo","year":"2000","journal-title":"J. Mol. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathy","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0161-6420(96)30560-5","article-title":"Lattice corneal dystrophy type II associated with familial amyloid polyneuropathy type IV","volume":"103","author":"Akiya","year":"1996","journal-title":"Ophthalmology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF00225202","article-title":"Asp187Asn mutation of gelsolin in an American kindred with familial amyloidosis, Finnish type (FAP IV)","volume":"95","author":"Steiner","year":"1995","journal-title":"Hum. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1136\/jmg.2003.014803","article-title":"Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy","volume":"41","author":"Ohmori","year":"2004","journal-title":"J. Med Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1469-1809.2008.00439.x","article-title":"On the origin of the transthyretin Val30Met familial amyloid polyneuropathy","volume":"72","author":"Zaros","year":"2008","journal-title":"Ann. Hum. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1212\/WNL.56.4.431","article-title":"Transthyretin-associated neuropathic amyloidosis pathogenesis and treatment","volume":"56","author":"Hund","year":"2001","journal-title":"Neurology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","article-title":"Transthyretin-related familial amyloidotic polyneuropathy","volume":"62","author":"Ando","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Suhr, O.B., Wixner, J., Anan, I., Lundgren, H.-E., Wijayatunga, P., Westermark, P., and Ihse, E. (2019). Amyloid fibril composition within hereditary Val30Met (p. Val50Met) transthyretin amyloidosis families. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211983"},{"key":"ref_49","first-page":"1771","article-title":"Type I (Transthyretin Met30) Familial Amyloid Polyneuropathy in Japan: Early- vs. Late-Onset Form","volume":"59","author":"Koike","year":"2002","journal-title":"JAMA Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/13506129.2018.1534731","article-title":"Epidemiology of ATTRV30M neuropathy in Cyprus and the modifier effect of complement C1q on the age of disease onset","volume":"25","author":"Andreou","year":"2018","journal-title":"Amyloid"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mus.20644","article-title":"Clinical variability in type I familial amyloid polyneuropathy (Val30Met): Comparison between late- and early-onset cases in Portugal","volume":"35","year":"2007","journal-title":"Muscle Nerve"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2019.05.030","article-title":"Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry","volume":"403","author":"Pinto","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2009.07.028","article-title":"Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy","volume":"287","author":"Koike","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_54","first-page":"182","article-title":"A DNA test for Indiana\/Swiss hereditary amyloidosis (FAP II)","volume":"43","author":"Wallace","year":"1988","journal-title":"Am. J. Hum. Genet."},{"key":"ref_55","unstructured":"Sekijima, Y., Yoshida, K., Tokuda, T., and Ikeda, S.-I. (2018). Familial Transthyretin Amyloidosis, Available online: https:\/\/rarediseases.info.nih.gov\/diseases\/656\/familial-transthyretin-amyloidosis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0002-9394(02)01838-X","article-title":"Vitreous opacities and outcome of vitreous surgery in patients with familial amyloidotic polyneuropathy","volume":"135","author":"Koga","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/brain\/122.10.1951","article-title":"Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan","volume":"122","author":"Misu","year":"1999","journal-title":"Brain"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2796.1989.tb00091.x","article-title":"Assessment of thyroid and adrenal function in patients with familial amyloidotic polyneuropathy","volume":"225","author":"OLOFSSON","year":"1989","journal-title":"J. Intern. Med."},{"key":"ref_59","first-page":"77","article-title":"Contemporary Reviews in Cardiovascular Medicine","volume":"116","author":"Connection","year":"2007","journal-title":"Circulation"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(92)90672-X","article-title":"A Danish kindred with familial amyloid cardiomyopathy revisited: Identification of a mutant transthyretinmethionine 111 variant in serum from patients and carriers","volume":"93","author":"Alves","year":"1992","journal-title":"Am. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"New Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am. Heart J."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Polimanti, R., Nu\u00f1ez, Y.Z., and Gelernter, J. (2019). Increased Risk of Multiple Outpatient Surgeries in African-American Carriers of Transthyretin Val122Ile Mutation Is Modulated by Non-Coding Variants. J. Clin. Med., 8.","DOI":"10.3390\/jcm8020269"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2006.01.042","article-title":"Transthyretin V122I in African Americans with congestive heart failure","volume":"47","author":"Buxbaum","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/humu.1132","article-title":"Transthyretin mutations in hyperthyroxinemia and amyloid diseases","volume":"17","author":"Saraiva","year":"2001","journal-title":"Hum. Mutat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/BF00225199","article-title":"Transthyretin Ser 6 gene frequency in individuals without amyloidosis","volume":"95","author":"Jacobson","year":"1995","journal-title":"Hum. Genet."},{"key":"ref_69","first-page":"3335","article-title":"A new family with hyperthyroxinemia caused by transthyretin Val109 misdiagnosed as thyrotoxicosis and resistance to thyroid hormone--a clinical research center study","volume":"81","author":"Refetoff","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e000364","DOI":"10.1161\/JAHA.111.000364","article-title":"Updates in cardiac amyloidosis: A review","volume":"1","author":"Banypersad","year":"2012","journal-title":"J. Am. Heart Assoc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/01.CIR.46.1.55","article-title":"Echocardiography in the Diagnosis of Hypoplasia of the Left or Right Ventricles in the Neonate","volume":"46","author":"MEYER","year":"1972","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Tissot, C., Singh, Y., and Sekarski, N. (2018). Echocardiographic Evaluation of Ventricular Function\u2014For the Neonatologist and Pediatric Intensivist. Front. Pediatrics, 6.","DOI":"10.3389\/fped.2018.00079"},{"key":"ref_75","first-page":"81","article-title":"The echocardiographic assessment of the right ventricle: What to do in 2010?","volume":"11","author":"Jurcut","year":"2010","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Lakshmanadoss, U. (2016). Assessment of right ventricle by echocardiogram. Echocardiography in Heart Failure and Cardiac Electrophysiology, IntechOpen Limited.","DOI":"10.5772\/61427"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.50.1.42","article-title":"Echocardiographic assessment of left ventricular function with special reference to normalized velocities","volume":"50","author":"Quinones","year":"1974","journal-title":"Circulation"},{"key":"ref_78","first-page":"260","article-title":"Assessment of Left Ventricular Function by Echocardiography: The Case for Routinely Adding Global Longitudinal Strain to Ejection Fraction","volume":"11","author":"Potter","year":"2018","journal-title":"JACC: Cardiovasc. Imaging"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0002-9440(10)63050-7","article-title":"Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: Evidence for toxicity of nonfibrillar aggregates","volume":"159","author":"Sousa","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/path.2411","article-title":"Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis","volume":"216","author":"Ihse","year":"2008","journal-title":"J. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/PAS.0000000000000430","article-title":"Distinctive patterns of transthyretin amyloid in salivary tissue: A clinicopathologic study of 92 patients with amyloid-containing minor salivary gland biopsies","volume":"39","author":"Jamet","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/PAS.0b013e3182263d74","article-title":"Strong tranthyretin immunostaining, potential pitfall in cardiac amyloid typing","volume":"35","author":"Satoskar","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ana.24972","article-title":"Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy","volume":"82","author":"Ebenezer","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/hmg\/ddi051","article-title":"Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: Complexity in a single-gene disease","volume":"14","author":"Soares","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13506120500107162","article-title":"A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population","volume":"12","author":"Yamashita","year":"2005","journal-title":"Amyloid"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neures.2006.08.014","article-title":"Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis","volume":"56","author":"Tojo","year":"2006","journal-title":"Neurosci. Res."},{"key":"ref_87","first-page":"I8","article-title":"Transthyretin as Potential Biomarker for C9ORF72-related Diseases (I8-2A)","volume":"84","author":"Finch","year":"2015","journal-title":"Neurology"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Sharma, M., Khan, S., Rahman, S., and Singh, L.R. (2019). The Extracellular Protein, Transthyretin Is an Oxidative Stress Biomarker. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.00005"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1523\/JNEUROSCI.2417-11.2011","article-title":"Neuronal Production of Transthyretin in Human and Murine Alzheimer\u2019s Disease: Is It Protective?","volume":"31","author":"Li","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"eaam7621","DOI":"10.1126\/scitranslmed.aam7621","article-title":"Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients","volume":"9","author":"Schonhoft","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00007890-199807270-00016","article-title":"Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: Implications for amyloid fibrillogenesis","volume":"66","author":"Stangou","year":"1998","journal-title":"Transplantation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","article-title":"Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)","volume":"40","author":"Holmgren","year":"1991","journal-title":"Clin. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.transproceed.2010.11.014","article-title":"Characterization of end-stage renal disease after liver transplantation in transthyretin amyloidosis (ATTR V30M)","volume":"43","author":"Rocha","year":"2011","journal-title":"Transplant. Proc."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1600-6143.2008.02162.x","article-title":"Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis","volume":"8","author":"Hamour","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/hep.20704","article-title":"AASLD practice guidelines: Evaluation of the patient for liver transplantation","volume":"41","author":"Murray","year":"2005","journal-title":"Hepatology"},{"key":"ref_96","first-page":"e154","article-title":"ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society","volume":"112","author":"Hunt","year":"2005","journal-title":"Circulation"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/mus.20503","article-title":"Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides","volume":"33","author":"Benson","year":"2006","journal-title":"Muscle Nerve"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/13506129.2012.673140","article-title":"Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy","volume":"19","author":"Ackermann","year":"2012","journal-title":"Amyloid"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/biot.201100054","article-title":"Current progress of siRNA\/shRNA therapeutics in clinical trials","volume":"6","author":"Burnett","year":"2011","journal-title":"Biotechnol. J."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Adams, D. (2012). Recent advances in the treatment of familial amyloid neuropathies. Ther. Adv. Neurol. Disord., 1756285612470192.","DOI":"10.1177\/1756285612470192"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/nmt-2018-0037","article-title":"Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis","volume":"9","author":"Benson","year":"2018","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_102","first-page":"570","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2018","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17512433.2019.1567326","article-title":"Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"12","author":"Yang","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0968-0896(99)00066-8","article-title":"Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid","volume":"7","author":"Baures","year":"1999","journal-title":"Bioorganic Med. Chem."},{"key":"ref_107","first-page":"107","article-title":"An update on treatments for amyloid heart disease","volume":"20","author":"Dubrey","year":"2013","journal-title":"Br. J. Cardiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/13506129.2011.574354073","article-title":"The diflunisal trial: Update on study drug tolerance and disease progression","volume":"18","author":"Berk","year":"2011","journal-title":"Amyloid"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"25080","DOI":"10.1038\/srep25080","article-title":"Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: A potential diagnostic and therapeutic for TTR amyloidoses","volume":"6","author":"Galant","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: Studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: A phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1107\/S2052252514021113","article-title":"Binding site asymmetry in human transthyretin: Insights from a joint neutron and X-ray crystallographic analysis using perdeuterated protein","volume":"1","author":"Haupt","year":"2014","journal-title":"IUCrJ"},{"key":"ref_113","unstructured":"Palmieri, L.C., Freire, J.B.B., Palhano, F.L., Azevedo, E.P.C., Foguel, D., and Lima, L.M.T.R. Crystal structure of human transthyretin variant A25T\u2014#1, in press."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/12\/2982\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:59:27Z","timestamp":1760187567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/12\/2982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":113,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["ijms20122982"],"URL":"https:\/\/doi.org\/10.3390\/ijms20122982","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]}}}